Epithelial ovarian cancer (EOC) is the one of the most dangerous killer among gynecological malignancies. In terms of incidence, it ranks 6th among all cancers in the world. It is the primary reason for morbidity and mortality in female related cancers. Despite improvement of surgical techniques and chemotherapy protocols, 5 year survival rate remains at 30%. Regarding impressive outcome in hematologic cancer treatment, CART therapy becomes the most promising immunotherapy. However, there’re still some hurdles for solid tumor treatment.
Recently, John Wahba and his colleagues demonstrated that the anti-tumor efficacy can be improve when combining chemotherapy and CART therapy in in vitro and in vivo models of EOC. Moreover, PD-L1 expression elevated on tumor cells after chemotherapy treatment, and PD-1 expression also upregulated on CART cells after co-culturing with tumor cells. Based on this finding, they combined chemotherapy, CART therapy and PD-1 blockade agent together for EOC treatment. The results indicated that the synergistic effects results in better efficacy in combinatorial therapy, compared to each treatment alone.
